サイクリン依存性キナーゼ様5(CDKL5)欠損症治療薬の世界市場:疫学予測

◆英語タイトル:Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Epidemiology Forecast to 2030
◆商品コード:DELV20JU187
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(187名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Understanding
CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004.

The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development.

The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two X’s, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females.

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Perspective by DelveInsight
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Detailed Epidemiology Segmentation
In the 7MM, the total prevalent population of CDD was estimated to be 16,397 cases in 2017.
The total diagnosed prevalent population of CDD in the seven major markets was 3,584 in 2017, which is expected to increase in the forecast period
In 2017, the total diagnosed prevalence of CDD in the United States was 208 in males and 1,315 in females
There are several types of clinical characteristics of CDD, among which, mainly eight types of characteristics are frequently observed. As per the estimates 1,234, 716, 1,142, 1,218, 1,317, 1,080, 976, 1,295, patients were affected by epileptic spasms, hypsarrhythmia, cortical visual impairment, hand stereotypies, gastrointestinal symptoms, constipation, reflux, and sleep difficulties in 2017.

Scope of the Report
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Report and Model provide an overview of the risk factors and global trends of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
The report provides the segmentation of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology

Report Highlights
Eleven-Year Forecast of CDD
7MM Coverage
Prevalence of CDD in 7MM
Diagnosed Prevalence of CDD in 7MM
Gender-specific Diagnosed Prevalence of CDD
Clinical Characteristics of CDD

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?
What are the key findings pertaining to the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?
What are the currently available treatments of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder?

Reasons to buy
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market
Quantify patient populations in the global Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder therapeutics in each of the markets covered
Understand the magnitude of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder population by its epidemiology
The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment and Management

6.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1: Summary of CDKL5 Deficiency Disorder (CDD), Epidemiology, and Key Events (2017–2030)

Table 2: Symptoms of CDD

Table 3: Common clinical characteristics and proposed minimal diagnostic criteria

Table 4: Total Prevalent Population of CDD in the 7MM (2017–2030)

Table 5: Total Diagnosed Prevalent Population of CDD in the 7MM (2017–2030)

Table 6: Prevalence of CDD in the United States (2017–2030)

Table 7: Diagnosed Prevalence of CDD in the United States (2017–2030)

Table 8: Gender-specific Diagnosed Prevalence of CDD in the United States (2017–2030)

Table 9: Clinical Characteristics of CDD in the United States (2017–2030)

Table 10: Prevalence of CDD in Germany (2017–2030)

Table 11: Diagnosed Prevalence of CDD in Germany (2017–2030)

Table 12: Gender-specific Diagnosed Prevalence of CDD in Germany (2017–2030)

Table 13: Clinical Characteristics of CDD in Germany (2017–2030)

Table 14: Prevalence of CDD in France (2017–2030)

Table 15: Diagnosed Prevalence of CDD in France (2017–2030)

Table 16: Gender-specific Diagnosed Prevalence of CDD in France (2017–2030)

Table 17: Clinical Characteristics of CDD in France (2017–2030)

Table 18: Prevalence of CDD in Italy (2017–2030)

Table 19: Diagnosed Prevalence of CDD in Italy (2017–2030)

Table 20: Gender-specific Diagnosed Prevalence of CDD in Italy (2017–2030)

Table 21: Clinical Characteristics of CDD in Italy (2017–2030)

Table 22: Prevalence of CDD in Spain (2017–2030)

Table 23: Diagnosed Prevalence of CDD in Spain (2017–2030)

Table 24: Gender-specific Diagnosed Prevalence of CDD in Spain (2017–2030)

Table 25: Clinical Characteristics of CDD in Spain (2017–2030)

Table 26: Prevalence of CDD in the United Kingdom (2017–2030)

Table 27: Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Table 28: Gender-specific Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Table 29: Clinical Characteristics of CDD in the United Kingdom (2017–2030)

Table 30: Prevalence of CDD in Japan (2017–2030)

Table 31: Diagnosed Prevalence of CDD in Japan (2017–2030)

Table 32: Gender-specific Diagnosed Prevalence of CDD in Japan (2017–2030)

Table 33: Clinical Characteristics of CDD in Japan (2017–2030)



List of Figures:

Figure 1: CDKL5 Deficiency Disorder (CDD) SWOT Analysis

Figure 2: Location of CDKL5 gene

Figure 3: X linked dominant inheritance

Figure 4: A schematic of the CDKL5 protein with variants from individuals with CDD evaluated in the CDKL5 Centers of Excellence (COEs)

Figure 5: Physiological CDKL5 substrates control cytoskeletal function.

Figure 6: Total Prevalent Patient Population of CDD in the 7MM (2017–2030)

Figure 7: Total Diagnosed Prevalent Patient Population of CDD in the 7MM (2017–2030)

Figure 8: Prevalence of CDD in the United States (2017–2030)

Figure 9: Diagnosed Prevalence of CDD in the United States (2017–2030)

Figure 10: Gender-specific Diagnosed Prevalence of CDD in the United States (2017–2030)

Figure 11: Clinical Characteristics of CDD in the United States (2017–2030)

Figure 12: Prevalence of CDD in Germany (2017–2030)

Figure 13: Diagnosed Prevalence of CDD in Germany (2017–2030)

Figure 14: Gender-specific Diagnosed Prevalence of CDD in Germany (2017–2030)

Figure 15: Clinical Characteristics of CDD in Germany (2017–2030)

Figure 16: Prevalence of CDD in France (2017–2030)

Figure 17: Diagnosed Prevalence of CDD in France (2017–2030)

Figure 18: Gender-specific Diagnosed Prevalence of CDD in France (2017–2030)

Figure 19: Clinical Characteristics of CDD in France (2017–2030)

Figure 20: Prevalence of CDD in Italy (2017–2030)

Figure 21: Diagnosed Prevalence of CDD in Italy (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalence of CDD in Italy (2017–2030)

Figure 23: Clinical Characteristics of CDD in Italy (2017–2030)

Figure 24: Prevalence of CDD in Spain (2017–2030)

Figure 25: Diagnosed Prevalence of CDD in Spain (2017–2030)

Figure 26: Gender-specific Diagnosed Prevalence of CDD in Spain (2017–2030)

Figure 27: Clinical Characteristics of CDD in Spain (2017–2030)

Figure 28: Prevalence of CDD in the United Kingdom (2017–2030)

Figure 29: Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Figure 30: Gender-specific Diagnosed Prevalence of CDD in the United Kingdom (2017–2030)

Figure 31: Clinical Characteristics of CDD in the United Kingdom(2017–2030)

Figure 32: Prevalence of CDD in Japan (2017–2030)

Figure 33: Diagnosed Prevalence of CDD in Japan (2017–2030)

Figure 34: Gender-specific Diagnosed Prevalence of CDD in Japan (2017–2030)

Figure 35: Clinical Characteristics of CDD in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[サイクリン依存性キナーゼ様5(CDKL5)欠損症治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆